Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 15/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664273 | 0.87 | GCK (0.45) | GCK | |
| SCHEMBL2668108 | 0.86 | GCK (0.47) | GCKIKBKBPTGS2 | |
| SCHEMBL2668246 | 0.77 | MEN1 (0.50) | GCKPTGS2 | |
| SCHEMBL2668134 | 0.76 | ENPP2 (0.47) | GCKPTGS2FYNMAP4K4MINK1 | |
| SCHEMBL9071202 | 0.74 | GCK (0.56) | GCKPTGS2 | |
| SCHEMBL2664272 | 0.72 | GCK (0.45) | GCKPTGS2 | |
| SCHEMBL1107750 | 0.71 | GCK (0.46) | GCKPTGS2 | |
| SCHEMBL12594323 | 0.71 | GCK (0.46) | GCK | |
| SCHEMBL2668121 | 0.70 | GCK (0.43) | GCKPTGS2 | |
| SCHEMBL178009 | 0.69 | ALDH1A1 (0.58) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173717-B9 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2173717-B1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL MYERS SQUIBB CO (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8273777-B2 | Glucokinase activators and methods of using same | BRISTOL-MEYER SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273777-B2 | Glucokinase activators and methods of using same | BRISTOL-MEYER SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100324071-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-23 | — | — | US | disclosed |
| US-20100324071-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-23 | — | — | US | disclosed |
| WO-2009018065-A2 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324071-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, HK1 | GCK 2/4885IKBKB 663/4885PTGS2 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.